Bone turnover markers in HIV-infected women on tenofovir-based antiretroviral therapy
Background: Tenofovir disoproxil fumarate (TDF) antiretroviral therapy is associated with disruption of the bone turnover process. Objectives: The objective of this study was to determine the association between tenofovir (TFV) plasma concentration and various bone turnover markers and compare thes...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AOSIS
2017-12-01
|
| Series: | Southern African Journal of HIV Medicine |
| Subjects: | |
| Online Access: | https://sajhivmed.org.za/index.php/hivmed/article/view/739 |
| _version_ | 1818008162393915392 |
|---|---|
| author | Mwila Mulubwa Michelle Viljoen Iolanthe M. Kruger Herculina S. Kruger Malie Rheeders |
| author_facet | Mwila Mulubwa Michelle Viljoen Iolanthe M. Kruger Herculina S. Kruger Malie Rheeders |
| author_sort | Mwila Mulubwa |
| collection | DOAJ |
| description | Background: Tenofovir disoproxil fumarate (TDF) antiretroviral therapy is associated with disruption of the bone turnover process.
Objectives: The objective of this study was to determine the association between tenofovir (TFV) plasma concentration and various bone turnover markers and compare these markers in HIV-infected women and HIV-uninfected controls.
Method: A cross-sectional sub-study included 30 HIV-infected women on TDF and 30 HIV-uninfected matched participants. Serum calcium (SrCa), serum phosphate (SrP), C-terminal telopeptide (CTx), parathyroid hormone (PTH), alkaline phosphatase (ALP), C-reactive protein (CRP), vitamin D (VitD) and bone mineral density (BMD) were measured. Plasma TFV was assayed on HPLC-MS/MS. The statistical tests applied were Mann–Whitney test, unpaired t-test, analysis of covariance, regression and correlation analysis.
Results: In HIV-infected women, no correlation existed between plasma TFV concentration and CTx, PTH, ALP, SrCa, SrP, VitD or BMD (p > 0.05). After adjusting for smoking and alcohol use, ALP (p < 0.001), CTx (p = 0.027) and PTH (p = 0.050) were significantly higher in HIV-infected compared to HIV-uninfected women. Women with TFV concentration ≥ 120 ng/mL had higher PTH concentrations (p = 0.037) compared to those with ≤ 100 ng/mL. Significant correlations between SrCa and PTH and SrCa and SrP including CTx and PTH (p < 0.05) were present in HIV-uninfected women while absent in HIV-infected counterparts (p > 0.05).
Conclusion: The results indicate possible increased bone turnover at higher TFV concentrations. The normal regular bone turnover processes in HIV-infected women on TDF therapy are altered. Larger studies are warranted to confirm these results. |
| first_indexed | 2024-04-14T05:25:35Z |
| format | Article |
| id | doaj.art-b600ae4b75d347f7b3ac0aa791a126b1 |
| institution | Directory Open Access Journal |
| issn | 1608-9693 2078-6751 |
| language | English |
| last_indexed | 2024-04-14T05:25:35Z |
| publishDate | 2017-12-01 |
| publisher | AOSIS |
| record_format | Article |
| series | Southern African Journal of HIV Medicine |
| spelling | doaj.art-b600ae4b75d347f7b3ac0aa791a126b12022-12-22T02:09:59ZengAOSISSouthern African Journal of HIV Medicine1608-96932078-67512017-12-01181e1e710.4102/sajhivmed.v18i1.739571Bone turnover markers in HIV-infected women on tenofovir-based antiretroviral therapyMwila Mulubwa0Michelle Viljoen1Iolanthe M. Kruger2Herculina S. Kruger3Malie Rheeders4Centre of Excellence for Pharmaceutical Sciences (Pharmacen), Division of Pharmacology, North-West UniversityCentre of Excellence for Pharmaceutical Sciences (Pharmacen), Division of Pharmacology, North-West University, South Africa; Department of Pharmacology and Clinical Pharmacy, School of Pharmacy, Faculty of Natural Sciences, University of the Western Cape, South AfricaAfrica Unit for Transdisciplinary Health Research (AUTHeR), North-West UniversityCentre of Excellence for Nutrition (CEN), North-West University, South Africa; Medical Research Council Hypertension and Cardiovascular Disease Research Unit, North-West University, South AfricaCentre of Excellence for Pharmaceutical Sciences (Pharmacen), Division of Pharmacology, North-West UniversityBackground: Tenofovir disoproxil fumarate (TDF) antiretroviral therapy is associated with disruption of the bone turnover process. Objectives: The objective of this study was to determine the association between tenofovir (TFV) plasma concentration and various bone turnover markers and compare these markers in HIV-infected women and HIV-uninfected controls. Method: A cross-sectional sub-study included 30 HIV-infected women on TDF and 30 HIV-uninfected matched participants. Serum calcium (SrCa), serum phosphate (SrP), C-terminal telopeptide (CTx), parathyroid hormone (PTH), alkaline phosphatase (ALP), C-reactive protein (CRP), vitamin D (VitD) and bone mineral density (BMD) were measured. Plasma TFV was assayed on HPLC-MS/MS. The statistical tests applied were Mann–Whitney test, unpaired t-test, analysis of covariance, regression and correlation analysis. Results: In HIV-infected women, no correlation existed between plasma TFV concentration and CTx, PTH, ALP, SrCa, SrP, VitD or BMD (p > 0.05). After adjusting for smoking and alcohol use, ALP (p < 0.001), CTx (p = 0.027) and PTH (p = 0.050) were significantly higher in HIV-infected compared to HIV-uninfected women. Women with TFV concentration ≥ 120 ng/mL had higher PTH concentrations (p = 0.037) compared to those with ≤ 100 ng/mL. Significant correlations between SrCa and PTH and SrCa and SrP including CTx and PTH (p < 0.05) were present in HIV-uninfected women while absent in HIV-infected counterparts (p > 0.05). Conclusion: The results indicate possible increased bone turnover at higher TFV concentrations. The normal regular bone turnover processes in HIV-infected women on TDF therapy are altered. Larger studies are warranted to confirm these results.https://sajhivmed.org.za/index.php/hivmed/article/view/739Tenofovir levelsBone turnover markersFemale HIV-infected |
| spellingShingle | Mwila Mulubwa Michelle Viljoen Iolanthe M. Kruger Herculina S. Kruger Malie Rheeders Bone turnover markers in HIV-infected women on tenofovir-based antiretroviral therapy Southern African Journal of HIV Medicine Tenofovir levels Bone turnover markers Female HIV-infected |
| title | Bone turnover markers in HIV-infected women on tenofovir-based antiretroviral therapy |
| title_full | Bone turnover markers in HIV-infected women on tenofovir-based antiretroviral therapy |
| title_fullStr | Bone turnover markers in HIV-infected women on tenofovir-based antiretroviral therapy |
| title_full_unstemmed | Bone turnover markers in HIV-infected women on tenofovir-based antiretroviral therapy |
| title_short | Bone turnover markers in HIV-infected women on tenofovir-based antiretroviral therapy |
| title_sort | bone turnover markers in hiv infected women on tenofovir based antiretroviral therapy |
| topic | Tenofovir levels Bone turnover markers Female HIV-infected |
| url | https://sajhivmed.org.za/index.php/hivmed/article/view/739 |
| work_keys_str_mv | AT mwilamulubwa boneturnovermarkersinhivinfectedwomenontenofovirbasedantiretroviraltherapy AT michelleviljoen boneturnovermarkersinhivinfectedwomenontenofovirbasedantiretroviraltherapy AT iolanthemkruger boneturnovermarkersinhivinfectedwomenontenofovirbasedantiretroviraltherapy AT herculinaskruger boneturnovermarkersinhivinfectedwomenontenofovirbasedantiretroviraltherapy AT malierheeders boneturnovermarkersinhivinfectedwomenontenofovirbasedantiretroviraltherapy |